10321 results for 'part devlin next'

An antibody–drug conjugate is not a targeted drug. It is a delivery problem with an antibody bolted to the front of it. Binding is the easy part, and it is almost never the part that fails. What deci

Platinum based cancer drugs Despite nearly 50% of all anti-cancer treatments being platinum-based, there is an urgent need to develop novel therapeutics

For decades, the fight against cancer has been a relentless battle of incremental gains. While immunotherapies like CAR-T cell therapy have offered revolutionary hope, their personalized nature, high

For decades, cancer drug development has focused on blocking proteins—inhibiting enzymes, antagonizing receptors, disrupting signaling pathways. Yet this approach leaves a vast landscape of disease-d

For years, the success of CAR-T cell therapy has been a beacon of hope in the fight against blood cancers, offering remarkable remissions where other treatments have failed. Yet, solid tumors—the form

Quick Facts About Ladiratuzumab VedotinWhat is Ladiratuzumab Vedotin?Ladiratuzumab Vedotin is an antibody-drug conjugate (ADC) designed to target LIV-1, a protein commonly expressed in t

A New Era in Oncology Chimeric Antigen Receptor (CAR)-T cell therapy represents a paradigm shift in the fight against cancer, offering a personalized and powerful immunotherapy that trains a patient

For decades, the fight against cancer has been a relentless battle of attrition, often with treatments that harm the body as much as the disease. But a new era of precision medicine is dawning, one th

Imagine a world where cancer treatment is no longer a blunt instrument but a precision-guided surgical strike, executed by the body's own immune system. For years, we have dreamed of 'smart' cells th

For decades, the fight against cancer has been a grueling battle of attrition, with treatments often as harsh as the disease itself. But a revolutionary approach, chimeric antigen receptor (CAR)-T cel

Imagine a living drug, engineered from a patient's own immune system, that can hunt down and destroy cancer cells with remarkable precision. This isn't science fiction; it's the reality of Chimeric An

Department of Oncology RetreatAssay Genie was honoured to sponsor and participate in the inaugural 2025 Department of Oncology Retreat, hosted by the University of Lausanne and Lausanne

We know it gets tiring being in the lab every day, especially with the evenings getting darker and gloomier. So, to get you in the festive spirit, we're holding a competition to win money to th

A chemokine gradient does not move a leukocyte anywhere. It only tells one that has already stopped which way to go. That sentence is the whole map. Trafficking is a four-step cascade and the steps a

Quick answer A researcher preparing a Human IL-18 ELISA wasn't sure whether the protocol's “300-fold” HRP-Streptavidin step meant adding 40 µL of concentrat

Showcasing Innovation Assay Genie recently took part in an engaging event at Oxford’s BioEscalator, a leading innovation hub supporting scientific progress and entrepreneurship. The day

Science communication (Scicomm) is currently on the up. As rebellion against the increasing distrust of science stemmed from bigoted and ignorant leaders, scientists are turning to s

Stress and anxiety are a normal part of our daily lives and impact everything we do from our relationships with loved ones to our performance in the laboratory. Like any scientist, I experienced s

An antibody's variable domains decide what it binds. Its Fc decides what happens next — and that is not a detail of formulation, it is half the mechanism. Which Fcγ receptor the constant region engag